Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.24
IRWD's Cash to Debt is ranked higher than
67% of the 1173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. IRWD: 1.24 )
IRWD' s 10-Year Cash to Debt Range
Min: 1.1   Max: N/A
Current: 1.24

Equity to Asset 0.22
IRWD's Equity to Asset is ranked lower than
52% of the 983 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. IRWD: 0.22 )
IRWD' s 10-Year Equity to Asset Range
Min: -1.86   Max: 0.74
Current: 0.22

-1.86
0.74
F-Score: 4
M-Score: 20.69
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -168.63
IRWD's Operating margin (%) is ranked lower than
53% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. IRWD: -168.63 )
IRWD' s 10-Year Operating margin (%) Range
Min: -1101.36   Max: -48.43
Current: -168.63

-1101.36
-48.43
Net-margin (%) -190.84
IRWD's Net-margin (%) is ranked lower than
53% of the 1117 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.55 vs. IRWD: -190.84 )
IRWD' s 10-Year Net-margin (%) Range
Min: -1192.31   Max: -48.34
Current: -190.84

-1192.31
-48.34
ROE (%) -145.40
IRWD's ROE (%) is ranked lower than
56% of the 1157 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.46 vs. IRWD: -145.40 )
IRWD' s 10-Year ROE (%) Range
Min: -299.34   Max: -48.14
Current: -145.4

-299.34
-48.14
ROA (%) -48.79
IRWD's ROA (%) is ranked lower than
54% of the 1183 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.53 vs. IRWD: -48.79 )
IRWD' s 10-Year ROA (%) Range
Min: -107.22   Max: -22.85
Current: -48.79

-107.22
-22.85
ROC (Joel Greenblatt) (%) -462.51
IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 1178 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.83 vs. IRWD: -462.51 )
IRWD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -672.79   Max: -194.55
Current: -462.51

-672.79
-194.55
Revenue Growth (3Y)(%) -5.30
IRWD's Revenue Growth (3Y)(%) is ranked higher than
57% of the 971 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. IRWD: -5.30 )
IRWD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: -5.3
Current: -5.3

EBITDA Growth (3Y)(%) 27.50
IRWD's EBITDA Growth (3Y)(%) is ranked higher than
92% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. IRWD: 27.50 )
IRWD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 52
Current: 27.5

0
52
EPS Growth (3Y)(%) 28.80
IRWD's EPS Growth (3Y)(%) is ranked higher than
90% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. IRWD: 28.80 )
IRWD' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 54.3
Current: 28.8

0
54.3
» IRWD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

IRWD Guru Trades in Q2 2014

Joel Greenblatt 27,789 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
John Burbank Sold Out
» More
Q3 2014

IRWD Guru Trades in Q3 2014

Steven Cohen 1,292,500 sh (New)
Vanguard Health Care Fund 3,901,498 sh (unchged)
Joel Greenblatt Sold Out
» More
Q4 2014

IRWD Guru Trades in Q4 2014

Steven Cohen 1,500,100 sh (+16.06%)
Vanguard Health Care Fund 4,166,598 sh (+6.79%)
» More
Q1 2015

IRWD Guru Trades in Q1 2015

Vanguard Health Care Fund 4,231,687 sh (+1.56%)
Steven Cohen 750,000 sh (-50.00%)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 48.31
IRWD's Forward P/E is ranked higher than
71% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. IRWD: 48.31 )
N/A
P/B 29.10
IRWD's P/B is ranked lower than
61% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. IRWD: 29.10 )
IRWD' s 10-Year P/B Range
Min: 5.46   Max: 46.91
Current: 29.1

5.46
46.91
P/S 21.50
IRWD's P/S is ranked lower than
69% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. IRWD: 21.50 )
IRWD' s 10-Year P/S Range
Min: 2.65   Max: 75.05
Current: 21.5

2.65
75.05
EV-to-EBIT -12.60
IRWD's EV-to-EBIT is ranked higher than
56% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 41.19 vs. IRWD: -12.60 )
IRWD' s 10-Year EV-to-EBIT Range
Min: -40   Max: -4.2
Current: -12.6

-40
-4.2
Current Ratio 4.41
IRWD's Current Ratio is ranked higher than
85% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.20 vs. IRWD: 4.41 )
IRWD' s 10-Year Current Ratio Range
Min: 2.33   Max: 9.64
Current: 4.41

2.33
9.64
Quick Ratio 4.33
IRWD's Quick Ratio is ranked higher than
87% of the 1051 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. IRWD: 4.33 )
IRWD' s 10-Year Quick Ratio Range
Min: 2.33   Max: 9.04
Current: 4.33

2.33
9.04
Days Inventory 183.04
IRWD's Days Inventory is ranked higher than
63% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 145.57 vs. IRWD: 183.04 )
IRWD' s 10-Year Days Inventory Range
Min: 193.31   Max: 1266.91
Current: 183.04

193.31
1266.91
Days Sales Outstanding 3.47
IRWD's Days Sales Outstanding is ranked higher than
99% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 91.38 vs. IRWD: 3.47 )
IRWD' s 10-Year Days Sales Outstanding Range
Min: 0.05   Max: 889.76
Current: 3.47

0.05
889.76

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 28.80
IRWD's Price/Tangible Book is ranked lower than
59% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. IRWD: 28.80 )
IRWD' s 10-Year Price/Tangible Book Range
Min: 6.43   Max: 36.28
Current: 28.8

6.43
36.28
Price/Median PS Value 1.00
IRWD's Price/Median PS Value is ranked higher than
86% of the 1290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.50 vs. IRWD: 1.00 )
IRWD' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 2.89
Current: 1

0.14
2.89
Earnings Yield (Greenblatt) -8.00
IRWD's Earnings Yield (Greenblatt) is ranked lower than
54% of the 1170 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. IRWD: -8.00 )
IRWD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -9.4   Max: 0
Current: -8

-9.4
0

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
IRONWOOD PHARMACEUTICALS INC Financials May 15 2015
Ironwood Presents Gastrointestinal Disease Research at Digestive Disease Week® 2015 May 13 2015
Ironwood Presents Gastrointestinal Disease Research at Digestive Disease Week® 2015 May 13 2015
10-Q for Ironwood Pharmaceuticals, Inc. May 08 2015
IBS in America: American Gastroenterological Association Initiates Comprehensive Survey of Patients... May 08 2015
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015
Ironwood Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Health Care Conference May 07 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report May 06 2015
Ironwood Q1 Loss Wider-Than-Expected, Revenues Miss - Analyst Blog May 06 2015
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update May 05 2015
Ironwood reports 1Q loss May 05 2015
Ironwood reports 1Q loss May 05 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 05 2015
Ironwood Pharmaceuticals Provides First Quarter 2015 Investor Update May 05 2015
Q1 2015 Ironwood Pharmaceuticals Inc Earnings Release - After Market Close May 05 2015
Key Analyst Sees Nearly 30% Upside in Ironwood Apr 27 2015
Coverage initiated on Ironwood Pharma by BofA/Merrill Apr 27 2015
Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors Apr 16 2015
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 16 2015
Ironwood Pharmaceuticals Appoints Lawrence Olanoff, M.D., Ph.D., to Board of Directors Apr 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK